{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.2","value":"40.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"}],"units":"Participants"}],"title":"C1D22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.8","value":"70.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.8","value":"97.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.9","value":"118.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"C7D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.2","value":"135.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"C9D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"}],"units":"Participants"}],"description":"Ctrough was defined as the predose concentration at the end of dosing interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\\^2 on C1D1 followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Participants also received up to 12 treatments of 5-fluorouracil, folinic acid and oxaliplatin (mFOLFOX6) (or components of mFOLFOX6 if some components were discontinued due to toxicity) over 4 or more cycles in which mFOLFOX6 was administered on Days 1, 15 and 29 of each cycle (5-fluorouracil administered by IV bolus 400 mg/m\\^2 over 5 to 15 minutes followed by 2400mg/m\\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid administered 400 mg/m\\^2 IV infusion over 2 hours; oxaliplatin administered 85 mg/m\\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.","id":"OG000","title":"mFOLFOX6 + Zolbetuximab"}],"paramType":"MEAN","populationDescription":"PKAS consisted of the subset of the SAF for which at least 1 zolbetuximab concentration measurement was available. Participants with available data at each timepoint were analyzed.","reportingStatus":"POSTED","timeFrame":"Predose on C1D22, C3D1, C5D1, C7D1, C9D1","title":"Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)","type":"SECONDARY","unitOfMeasure":"micrograms/mililiter (ug/mL)"}